WHOCC
Postal address:
WHO Collaborating Centre for Drug Statistics Methodology
Norwegian Institute of Public Health
Postboks 222 Sk°yen
0213 Oslo
Norway

Visiting/delivery address:
Sandakerveien 24C
Bygg C
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

New ATC codes 2019

ATC codeATC level name
L01XE50abemaciclib
C02KX52ambrisentan and tadalafil
C01CX09angiotensin II
L02BB05apalutamide
J05AR23atazanavir and ritonavir
L01XC32atezolizumab
B02BX08avatrombopag
L01XC31avelumab
C09DX06candesartan, amlodipine and hydrochlorothiazide
N03AX24cannabidiol
B01AX07caplacizumab
J01DD64cefpodoxime and beta-lactamase inhibitor
J01DD18cefteram
L04AA40cladribine 1)
R03CC63clenbuterol and ambroxol
L01XX61copanlisib
D11AH06crisaborole
A07XA06crofelemer
L01XY01cytarabine and daunorubicin
L01XE47dacomitinib
G01AX17dapivirine
J01MA23delafloxacin
J05AG06doravirine
D04AX01doxepin
N07XX14edaravone
L04AA39emapalumab
L01XX59enasidenib
L01XE46encorafenib
J05AX17enisamium iodide
L01XX58epacadostat
J01AA13eravacycline
A10BK04ertugliflozin
G04CX04fexapotide
P01CA03fexinidazole
L01BC09floxuridine
B02BX09fostamatinib
N02CX08galcanezumab
A10BH52gemigliptin and rosuvastatin
J05AP57glecaprevir and pibrentasvir
D11AX25hydrogen peroxide
J05AX23ibalizumab
M05BB09ibandronic acid and colecalciferol
L01XE48icotinib
V04CX01indocyanine green
A10BK05ipragliflozin
J04AM08isoniazid, sulfamethoxazole, trimethoprim and pyridoxine
J05AR24lamivudine, tenofovir disoproxil and doravirine
B06AC05lanadelumab
J05AX18letermovir
L02AE51leuprorelin and bicalutamide
L01XE44lorlatinib
B02BX07lusutrombopag
G03AA17medroxyprogesterone and estradiol
J01DH52meropenem and vaborbactam
A10BD23metformin and ertugliflozin
A10BD25metformin, saxagliptin and dapagliflozin
A06AH05naldemedine
L01XE45neratinib
G03AB09norgestimate and ethinylestradiol
S01EX06omidenepag
G03XXOther sex hormones and modulators of the genital system
L04AA38ozanimod
N07XX12patisiran
J05AX21pentanedioic acid imidazolyl ethanamide
J05AH03peramivir
G03XX01prasterone
S01XA26riboflavin
J04AM07rifampicin, ethambutol and isoniazid
B03XA05roxadustat
A10BD24sitagliptin and ertugliflozin
L01XX60talazoparib
J01DH06tebipenem pivoxil
A16AX15telotristat
L04AC17tildrakizumab
J05AX19tilorone
J01MA22tosufloxacin
D10AD06trifarotene
L01AD08uramustine
G02BB02vaginal ring with progestogen
N07XX13valbenazine
C09DX05valsartan and nebivolol
1) Oral formulations indicated for multiple sclerosis. Parenteral formulations are classified in L01BB04

Last updated: 2018-11-21